### Abstract

Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

Original language | English (US) |
---|---|

Pages (from-to) | 494-500 |

Number of pages | 7 |

Journal | Journal of Clinical Oncology |

Volume | 17 |

Issue number | 2 |

State | Published - Feb 1 1999 |

### Fingerprint

### ASJC Scopus subject areas

- Cancer Research
- Oncology

### Cite this

*Journal of Clinical Oncology*,

*17*(2), 494-500.

**Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.** / Grann, Victor R.; Whang, William; Jacobson, Judith S.; Heitjan, Daniel F.; Antman, Karen H.; Neugut, Alfred I.

Research output: Contribution to journal › Article

*Journal of Clinical Oncology*, vol. 17, no. 2, pp. 494-500.

}

TY - JOUR

T1 - Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2

AU - Grann, Victor R.

AU - Whang, William

AU - Jacobson, Judith S.

AU - Heitjan, Daniel F.

AU - Antman, Karen H.

AU - Neugut, Alfred I.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

AB - Purpose: To determine the survival benefit and cost-effectiveness of screening Ashkenazi Jewish women for three specific BRCA 1/2 gene mutations. Methods: We used a Markov model and Monte Carlo analysis to estimate the survival benefit and cost-effectiveness of screening for three specific mutations in a population in which their prevalence is 2.5% and the associated cancer risks are 56% for breast cancer and 16% for ovarian cancer. We assumed that the sensitivity and specificity of the test were 98% and 99%, respectively, that bilateral prophylactic oophorectomy would reduce ovarian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk by 90%. We used Medicare payment data far treatment costs and Surveillance, Epidemiology, and End Results data for cancer survival. Results: Our model suggests that genetic screening of this population could prolong average nondiscounted survival by 38 days (95% probability interval, 22 to 57 days) for combined surgery, 33 days (95% probability interval, 18 to 43 days) for mastectomy 11 days (95% probability interval, 4 to 25 days) for oophorectomy, and 6 days (95% probability interval, 3 to 8 days) for surveillance. The respective cost-effectiveness ratios per life-year saved, with a discount rate of 3%, are $20,717, $29,970, $72,780, and $134,273. Conclusion: In this Ashkenazi Jewish population, with a high prevalence of BRCA1/2 mutations, genetic screening may significantly increase average survival and, depending on costs and screening/treatment strategies, may be cost-effective by the standards of accepted cancer screening tests. According to our model, screening is cost-effective only if all women who test positive undergo prophylactic surgery. These estimates require confirmation through prospective observational studies and clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0033015788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033015788&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 494

EP - 500

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -